Eptifibatide
ATLPC0004545
Mpr-Har-GDWPC
- Length11 aa
- Monoisotopic mass1324.6 Da
- Net charge @ pH 7.41.10
- Isoelectric point8.56
- GRAVY-1.273
- Measurements11
- Endpoints7
- Domains4/5
- Products1
Open the matching evidence section below
Sequence & molecular identity
1 formsReviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.
Sequence & peptidoform
A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.
Identity summarySpecific molecular form represented
- Identity status
- Specific molecular form represented
- Residues
- 11
- Peptidoform features
- 4
- Documented molecular forms
- 1
- Representations
- 2
Documented molecular forms1 form linked to this peptide identity
| Form | Topology | Modifications | Connections | Representations | Measurements | |
|---|---|---|---|---|---|---|
| ATLPF0004951 | — | — | — | Notation only | 2 |
Residue view
Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.
Features are shown only when a reported notation or topology record supports them.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.
Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.
Structure & chemistry
Chemical representationsequence / HELM only
How the current release can interpret this identity chemically.
modified or textualResidue string used for positional interpretation when available.
MPRHARGDWPCPolymer notation for modified peptide representation when available.
Not availableChemical graph string used for atom-level 2D depiction when available.
Not availableA reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.
3D structure referencesnone attached
A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.
Covalent topology & modificationsnone
No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.
Physicochemical profile
Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.
Core descriptors11 aa · pI 8.6 · GRAVY -1.27
- Length
- 11 aa
- Monoisotopic mass
- 1324.59 Da
- Average mass
- 1325.53 Da
- Net charge at pH 7.4
- 1.10
- Estimated pI
- 8.56
- GRAVY
- -1.273
- KD-positive residues
- 27.3%
- Aromatic residues
- 9.1%
Developability interpretation
- Ionization context
- pH 7.4 separated from pI
- Hydrophobicity balance
- Leans hydrophilic
- Amphipathic moment (μH)
- 0.77
- Computation boundary
- Standard-sequence only
Charge & residue composition
Modeled net charge across common formulation and assay pH checkpoints.
Grouped composition is often more interpretable than a long amino-acid list.
Hydropathy & amphipathic windows
Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.
Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.
Sequence-liability cues
Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.
Alpha-helix amphipathic projection
The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.
Method notes
Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.
Exposure / Absorption
3 recordsWhat evidence describes systemic exposure or absorption?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
AUC1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 43.08 mg*h/L | Eligible when experimental context matches | Manual gap-fill extraction from NCATS FRDB v1.5 frdb-pk.tsv with primary source URI retained · human · plasma | Result: Reported point value · Molecular form: not reported · Route: intravenous · Source: Primary reference linked | Reference |
Cmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 879 ng/mL | Eligible when experimental context matches | Manual extraction from PubMed-indexed clinical PK abstract; 14C-eptifibatide IV bolus disposition study · human · plasma | Result: Reported point value · Molecular form: not reported · Route: intravenous · Time: 5 min · Source: Primary reference linked | Reference |
Tmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 5 min 300 seconds | Eligible when experimental context matches | Manual extraction from PubMed-indexed clinical PK abstract; 14C-eptifibatide IV bolus disposition study · human · plasma | Result: Reported point value · Molecular form: not reported · Route: intravenous · Time: 5 min · Source: Primary reference linked | Reference |
Distribution / Barrier
3 recordsWhat is known about distribution, binding, permeability, or barrier crossing?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 0.17 L/kg | Eligible when experimental context matches | Volume of distribution at steady state in human after iv administration · human | Result: Reported point value · Molecular form: not reported · Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... · Source: Primary reference linked | Reference |
Plasma protein binding2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | ~ 25 % | Use only explicitly reported fields | human · plasma | Result: Approximate quantitative measurement · Molecular form: not reported · Eptifibatide· 12.3 Pharmacokinetics · plasma binding human plasma protein percent · The e... · Source: Primary reference linked | Reference |
| 2 | 25 % | Use only explicitly reported fields | plasma protein | Result: Reported point value · Molecular form: not reported · Route: IV · 1 · Eptifibatide · exact product name match · exact or normalized match · Source: Primary reference linked | Source record |
Barrier and permeability assay context
PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.
artificial membrane
cell monolayer
cell monolayer
cell monolayer
barrier evidence
Metabolic & Proteolytic Stability
2 recordsHow stable is the peptide in biological matrices or protease systems?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Serum/plasma stability2 records · 0 matched-context · 0 as reported · 0 context only · 2 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 18000 seconds | Review experimental context before comparison | Not specified | Result: Reported point value · Molecular form: ATLPF0004951 · Source: Primary reference linked | Reference |
| 2 | 4067.9999999999995 seconds | Review experimental context before comparison | Not specified | Result: Reported point value · Molecular form: ATLPF0004951 · Source: Primary reference linked | Reference |
Excretion / Persistence
3 recordsWhat evidence describes clearance or persistence?
Evidence interpretation
Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.
Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.
Clearance3 records · 1 matched-context · 2 as reported · 0 context only · 0 review required
| # | Value | Analysis use | Assay / model | Result context | Reference |
|---|---|---|---|---|---|
| 1 | 1.2 mL/min/kg | Eligible when experimental context matches | Clearance in human after iv administration · human | Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name EPTIF... · Source: Primary reference linked | Reference |
| 2 | Observation In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. | Interpret as reported | human | Result: Qualitative or narrative result · Molecular form: not reported · Eptifibatide· 12.3 Pharmacokinetics · renal clearance fraction of total clearance text ·... · Source: Primary reference linked | Reference |
| 3 | ~ 55 mL/kg/h | Use only explicitly reported fields | human | Result: Approximate quantitative measurement · Molecular form: not reported · Eptifibatide· 12.3 Pharmacokinetics · clearance single · Clearance in patients with coron... · Source: Primary reference linked | Reference |
Evidence landscape
11 recordsCross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.
A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.
Top evidence-bearing endpoint questions.
Broad context buckets, useful before comparing values.
Reference-link availability for measurement-level audit.
Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.
| # | ADMET domain | Endpoint | Reported value | Result type | Analysis use | Assay / model | Condition | Reference |
|---|---|---|---|---|---|---|---|---|
| 1 | Metabolic & Proteolytic Stability Stability | Serum Plasma Stability | 18,000 seconds | Reported point value | Review experimental context before comparison | Not specified | Not specified | Reference Primary reference linked |
| 2 | Metabolic & Proteolytic Stability Stability | Serum Plasma Stability | 4,068 seconds | Reported point value | Review experimental context before comparison | Not specified | Not specified | Reference Primary reference linked |
| 3 | Distribution / Barrier Distribution | Plasma Protein Binding | 25 % | Reported point value | Use only explicitly reported fields | plasma protein | Route: IV | Source record Primary reference linked |
| 4 | Distribution / Barrier Distribution | Volume Of Distribution | 0.17 L/kg | Reported point value | Eligible when experimental context matches | Volume of distribution at steady state in human after iv administration · human | Route: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein | Reference Primary reference linked |
| 5 | Excretion / Persistence Persistence | Clearance | 1.2 mL/min/kg | Reported point value | Eligible when experimental context matches | Clearance in human after iv administration · human | Route: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein | Reference Primary reference linked |
| 6 | Exposure / Absorption Exposure | Max Concentration | 879 ng/mL | Reported point value | Eligible when experimental context matches | Manual extraction from PubMed-indexed clinical PK abstract; 14C-eptifibatide IV bolus disposition study · human · plasma | Route: intravenous · Time: 5 min · The abstract states peak plasma eptifibatide concentration was achieved at the first sampling time, 5 minutes. Retain this as study-level Cmax evidence, n... | Reference Primary reference linked |
| 7 | Exposure / Absorption Exposure | Time To Max Concentration | 5 min 300 seconds | Reported point value | Eligible when experimental context matches | Manual extraction from PubMed-indexed clinical PK abstract; 14C-eptifibatide IV bolus disposition study · human · plasma | Route: intravenous · Time: 5 min · The abstract identifies the Cmax sampling time as the first post-dose plasma sample at 5 minutes. Store as a sampling-limited Tmax evidence observation, n... | Reference Primary reference linked |
| 8 | Exposure / Absorption Exposure | Area Under Curve | 43.08 mg*h/L | Reported point value | Eligible when experimental context matches | Manual gap-fill extraction from NCATS FRDB v1.5 frdb-pk.tsv with primary source URI retained · human · plasma | Route: intravenous · Exact FRDB compound-name and UNII match to Eptifibatide. This is a study-level AUC observation for a 24-hour IV infusion context, not a universal approved-regimen produ... | Reference Primary reference linked |
| 9 | Excretion / Persistence Persistence | Clearance | Observation In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites. | Qualitative or narrative result | Interpret as reported | human | Not specified | Reference Primary reference linked |
| 10 | Distribution / Barrier Distribution | Plasma Protein Binding | ~ 25 % | Approximate quantitative measurement | Use only explicitly reported fields | human · plasma | Not specified | Reference Primary reference linked |
Product context
1 productsProduct-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.
Summary1 linked product
- Linked products
- 1
- Label context
- None
- Clinical trials
- 25
- Safety label cues
- None
Linked products1 shown
Eptifibatide
Identity & reference map
11 sourcesReference-level support for checking reported names, sequence notation, and peptide identity agreement.
Summary5 reference groups
- Identity type
- reported modified sequence
- Reported notation
- 1
- Reference groups
- 5
- Measurements
- 11
- ATL peptide ID
- ATLPC0004545
Identity concordance
Reported sequence string matches the current peptide notation.
Reported notation differs, but resolves to the same parent-residue display.
Reported notation does not resolve to the current display sequence.
No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.
XXGDWPC-NH2
Mpr-Har-GDWPC
Reference map5 reference groups
Grouped by reference link, with endpoint scope and reported identity kept visible.
| Reference | Supports | Reported identity | Records |
|---|---|---|---|
Reference | ExposureStability Max Concentration, Serum Plasma Stability, Time To Max Concentration | No reported alias | 4 identity 4 evidence |
Reference | DistributionPersistence Clearance, Plasma Protein Binding | No reported alias | 3 identity 3 evidence |
Reference | DistributionPersistence Clearance, Volume Of Distribution | No reported alias | 2 identity 2 evidence |
Source record | Distribution Plasma Protein Binding | No reported alias XXGDWPC-NH2different | 1 identity 1 evidence |
Reference | Exposure Area Under Curve | No reported alias | 1 identity 1 evidence |
Data access & reproducibility
Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.
Record scopePublic release
- ATL peptide ID
- ATLPC0004545
- Identity type
- reported modified sequence
- ADMET endpoints
- 7
- Evidence records
- 11
- Reference groups
- 5
- Release view
- Public release
Data access
Structured peptide profile
JSONPeptide-specific profile used by this page, including identity and evidence context.
Peptide catalogue
TSVComplete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.
Measurement catalogue
TSVComplete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.
Programmatic access
The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0004545' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'